HIV-1 Vpr: A closer look at the multifunctional protein from the structural perspective

Current HIV Research

Volumn 7, Issue 2, 2009, Pages 114-128

  Pandey, Ramesh C ^a   Datta, Debduti ^a   Mukerjee, Ruma ^b   Srinivasan, Alagarsamy ^c   Mahalingam, Sundarasamy ^a   Sawaya, Bassel E ^b  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NanoBio Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; STRESS ACTIVATED PROTEIN KINASE; TRANSACTIVATOR PROTEIN; VPR PROTEIN; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO TERMINAL SEQUENCE; APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELLULAR DISTRIBUTION; DNA DAMAGE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEAR MAGNETIC RESONANCE; POINT MUTATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURAL BIOINFORMATICS; STRUCTURAL PROTEOMICS; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; TRIPLE HELIX; VIRION; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSCRIPTION; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE;

HIV-1; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 64749112949     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209787581508     Document Type: Review

References (105)

1. Weiss RA. How does HIV cause AIDS? Science 1993; 260: 1273-9.
2. Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981; 305:1439-44.
3. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305: 1425-31.
4. Friedman-Kien AE. Disseminated Kaposi's sarcoma syndrome in young homosexual men. J Am Acad Dermatol 1981; 5: 468-71.
5. Gallo RC. A refection on HIV/AIDS research after 25 years. Retrovirology 2006; 3: 72.
6. Barre-Sinoussi F, Chermann JC, Rey F, et al, Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
7. Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo RC. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 1984; 224: 506-8.
8. Kallings LO. The first postmodern pandemic: 25 years of HIV/AIDS. J Intern Med 2008; 263: 218-43.
9. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397: 436-41.
10. Santiago ML, Rodenburg CM, Kamenya S, et al. SIVcpz in wild chimpanzees. Science 2002; 295: 465.
11. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006; 313: 523-6.
12. Pantaleo G, Graziosi C, Fauci AC. The immunopathogenesis of Human immune deficiency virus infection. N Engl J Med 1993; 328: 327-35.
13. Poli G, Fauci AS. The role of monocytes/macrophages and cytokines in the pathogenesis of human immunodeficiency virus infection. Pathobiology 1992; 60: 246-51.
14. Levy JA. HIV and the pathogenesis of AIDS. 1998. (ASM Press, Washington, DC).
15. Jowett JBM, Planelles V, Poon B, Shah NP, Chen ML, Chen ISY. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 1 M phase of the cell cycle. J Virol 1995; 69: 6304-13.
16. Herbein G, Van Lint C, Lovett J, Verdin E. Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-Infected and in uninfected bystander T lymphocytes. J Virol 1998; 72: 660-70.
17. Arthur LO, Bess JJ, Sowder RC, et al. Cellular proteins bound to immunodeficiency viruses: implications forpathogenesis and vaccines. Science 1992; 258: 1935-8.
18. Cohen EA, Dehni G, Sodroski JG, Haseltine WA. Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol 1990; 64: 3097-9.
19. Henderson LE, Sowder RC, Copeland TD, Benveniste RE, Oroszlan S. Isolation and characterization of a novel protein (XORF product) from SIV and HIV-2. Science 1988; 241:199-201.
20. Yu XF, Matsuda M, Essex M, Lee TH. Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein. J Virol 1990; 64: 5688-93.
21. Tungaturthi PK, Sawaya BE, Singh SP, et al. Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intravirion, intracellular and free Vpr. Biomed Pharmacother 2003; 57: 20-4.
22. Levy DN, Fernandes LS, Williams WV, Weiner DB. Induction of cell differentiation by human immunodeficiency virus 1 Vpr. Cell 1993; 72: 541-50.
23. Popov M, Rexach M, Zybarth G, et al. Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J 1998; 17: 909-17.
24. Goh WC, Rogel ME, Kinsey CM, et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 1998; 4: 65-71.
25. Muthumani K, Hwang DS, Desai BM, et al. HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 2002; 277: 37820-31.
26. Heinzinger NK, Bukrinsky MI, Haggerty SA, et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in non-dividing host cells. Proc Natl Acad Sci USA 1994; 91: 7311-5.
27. Noronha CM, Sherman MP, Lin HW, et al. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 2001; 294: 1105-8.
28. Chang F, Re F, Sebastian S, Sazer S, Luban J. HIV-1 Vpr induces defects in mitosis, cytokinesis, nuclear structure, and centrosomes, Mol Biol Cell 2004; 154: 1793-801.
29. Morellet N, Bouaziz S, Lenoir C, Roques BP. NMR structure of the HIV-1 regulatory protein vpr. J Mol Biol 2003; 327: 215-27.
30. Bourbigot S, Beltz H, Denis J, et al. The C-terminal domain of the HIV-1 regulatory protein Vpr adopts an antiparallel dimeric structure in solution via its leucine-zipper-like domain. Biochem J 2005; 387: 333-41.
31. Wecker K, Roques BP. NMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein Vpr. Eur J Biochem 1999; 266: 359-69.
32. Bruns K, Fossen T, Wray V, Henklein P, Tessmer U, Schubert U. Structural characterization of the HIV-1 Vpr N terminus: evidence of cis/ trans-proline isomerism. J Biol Chem 2003; 278: 43188-201.
33. Zander K, Sherman MP, Tessmer U, et al. Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression. J Biol Chem 2003; 278: 43202-13.
34. Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol 1995; 69: 7032-44.
35. Thotala D, Schafer EA, Tungaturthi PK, et al. Structure-functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication. Virology 2004; 328: 89-100.
36. Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA. Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. J Biol Chem 1999; 274: 9083-91.
37. Selig L, Pages JC, Tanchou V, et al. Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J Virol 1999; 73: 592-600.
38. De Rocquigny H, Petitjean P, Tanchou V, et al. The zinc fingers of HIV nucleocapsid protein NCp7 direct interactions with the viral regulatory protein Vpr. J Biol Chem 1997; 272: 30753-9.
39. Dehart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Argañaraz ER, Planelles V. HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 2007; 4: 57.
40. Mahalingam S, Khan SA, Murali R, et al. Mutagenesis of the putative α-helical domain of the Vpr protein of HIV-1: effect on stability and virion incorporation. Proc Natl Acad Sci 1995; 92: 3794-8.
41. Lu YL, Bennett RP, Wills JW, Gorelick R, Ratner L. A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol 1995; 69: 6873-9.
42. Accola MA, Strack B, Gottlinger HG. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol 2000; 74: 5395-402.
43. Kobinger GP, Borsetti A, Nie Z, et al. Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J Virol 1998; 72: 5441-8.
44. Singh SP, Tungaturthi P, Cartas M, et al. Virion-associated HIV-1 Vpr: variable amount in virus particles derived from cells upon virus infection on proviral DNA transfection. Virology 2001; 283: 78-83.
45. Accola MA, Öhagen A, Göttlinger HG. Isolation of Human Immunodeficiency Virus Type 1 Cores: retention of Vpr in the absence of p6gαg. J Virol 2000; 74: 6198-202.
46. Zhu Y, Gelbard HA, Roshal M, Pursell S, Jamieson BD, Planelles V. Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes; J Virol 2001; 75: 3791-801.
47. Huard S, Elder RT, Liang D, Li G, Zhao RY. Human immunodeficiency virus type 1 Vpr induces cell cycle G2 arrest through Srk1/MK2-mediated phosphorylation of Cdc25. J Virol 2008; 82: 2904-17.
48. Zhao RY, Elder RT. Viral infections and cell cycle G2/M regulation. Cell Res 2005; 15: 143-9.
49. Bartz SR, Rogel ME, Emerman M. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol 1996; 70: 2324-31.
50. Chowdhury IH, Wang XF, Landau NR, et al. HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest. Virology 2003; 305: 371-7.
51. Yuan H, Kamata M, Xie YM, Chen IS. Increased levels of Wee-1 kinase in G(2) are necessary for Vpr- and gamma irradiation-induced G(2) arrest. J Virol 2004; 78: 8183-90.
52. Masuda M, Nagai Y, Oshima N, et al. Genetic studies with the fission yeast Schizosaccharomyces pombe suggest involvement of wee1, ppa2, and rad24 in induction of cell cycle arrest by human immunodeficiency virus type 1 Vpr. J Virol 2000; 74: 2636-46.
53. Kamata M, Watanabe N, Nagaoka Y, Chen IS. Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2. J Virol 2008; 82: 5672-82.
54. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 2003; 278: 25879-86.
55. Zimmerman ES, Chen J, Andersen JL, et al. Human immunodeficiency virus type 1 Vpr-mediated G2 arrest require Rad17 and Hus1 and induces nuclear BRCA1 and {gamma}-H2AX focus formation. Mol Cell Biol 2004; 24: 9286-94.
56. Ramanathan MP, Curley E, 3rd, Su M, Chambers JA, Weiner DB. Carboxyl terminus of hVIP/mov34 is critical for HIV-1-Vpr interaction and glucocorticoid-mediated signalling. J Biol Chem 2002; 277: 47854-60.
57. Gragerov A, Kino T, Ilyina-Gragerova G, Chrousos GP, Pavlakis GN. HHR23A, the human homologue of the yeast repair protein RAD23, interacts specifically with Vpr protein and prevents cell cycle arrest but not the transcriptional effects of Vpr. Virology 1998; 245: 323-30.
58. Lai M, Zimmerman ES, Planelles V, Chen J. Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J Virol 2005; 79: 15443-51.
59. Terada Y, Yasuda Y. Human immunodeficiency virus type 1 Vpr induces G2 checkpoint activation by interacting with the splicing factor SAP145. Mol Cell Biol 2006; 26: 8149-58.
60. Wen X, Duus KM, Friedrich TD, de Noronha CM. The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem 2007; 282: 27046-57.
61. Agostini I, Popov S, Hao T, et al. Phosphorylation of Vpr Regulates HIV Type 1 Nuclear Import and Macrophage Infection. AIDS Res Hum Retroviruses 2002; 18: 283-8.
62. Zhou Y, Ratner L. Phosphorylation of human immunodeficiency virus type 1 Vpr regulates cell cycle arrest. J Virol 2000; 74: 6520-7.
63. Chen M, Elder RT, Yu M, et al. Mutational analysis of Vpr-induced G2 arrest, nuclear localization, and cell death in fission yeast. J Virol 1999; 73: 3236-45.
64. Stewart SA, Poon B, Jowet JB, Chen IS. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 1997; 71: 5579-92.
65. Conti L, Rainaldi G, Matarrese P, et al. The HIV-1 Vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: possible implications for the pathogenesis of AIDS. J Exp Med 1998; 187: 403-13.
66. Azuma A, Matsuo A, Suzuki T, Kurosawa T, Zhang X, Aida Y. Human immunodeficiency virus type 1 Vpr induces cell cycle arrest at the G(1) phase and apoptosis via disruption of mitochondrial function in rodent cells. Microbes Infect 2006; 8: 670-9.
67. Stewart SA, Poon B, Song JY, Chen IS. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation, J Virol 2000; 74: 3105-11.
68. Jacotot E, Ravagnan L, Loeffler M, et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000; 191: 33-46.
69. Muthumani K, Choo AY, Hwang DS, et al. Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem Biophy Res Commun 2003; 304: 583-92.
70. Vieira HL, Haouzi D, El Hamel C, et al. Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator. Cell Death Differ 2000; 7: 1146-54.
71. Roumier T, Vieira HL, Castedo M, et al. The C-terminal moiety of HIV-1 Vpr induces cell death via a caspase-independent mitochondrial pathway. Cell Death Differ 2002; 9: 1212-9.
72. Muthumani K, Zhang D, Hwang DS, et al. Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. Oncogene 2002; 21: 4613-25.
73. Mishra S, Mishra JP, Kumar A. Activation of JNK-dependent pathway is required for HIV viral protein R-induced apoptosis in human monocytic cells: involvement of antiapoptotic BCL2 and c-IAP1 genes. J Biol Chem 2007; 282: 4288-300.
74. Andersen JL, Zimmerman ES, Dehart JL, et al. ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis, Cell Death Differ 2005; 12: 326-34.
75. Sabbah EN, Druillennec S, Morellet N, Bouaziz S, Kroemer G, Roques BP. Interaction between the HIV-1 protein Vpr and the adenine nucleotide translocator. Chem Biol Drug Des 2006; 67: 145-54
76. Marzo I, Brenner C, Zamzami N, et al. The permeability transition pore complex: a target for apoptosis regulation by caspases and Bcl-2-related Proteins. J Exp Med 1998; 187: 1261-71.
77. Forget J, Yao XJ, Mercier J, Cohen EA, Human immunodeficiency virus type 1 vpr protein transactivation function: mechanism and identification of domains involved. J Mol Biol 1998; 284: 915-23.
78. Vanitharani R, Mahalingam S, Rafaeli Y, et al. HIV-1 Vpr transactivates LTR-directed expression through sequences present within - 278 to -176 and increases virus replication in vitro. Virology 2001; 289: 334-42.
79. Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 1995; 270: 25564-9.
80. Jakobovits A, Rosenthal A, Capon DJ. Trans-activation of HIV-1 LTR-directed gene expression by tat requires protein kinase C. EMBO J 1990; 9: 1165-70.
81. Felzien LK, Woffendin C, Hottiger MO, Subbramanian R, Cohen EA, Nabel GJ. HIV transcriptional activation by the accessory protein, Vpr, is mediated by the p300 co-activator. Proc Natl Acad Sci USA 1998; 95: 5281-6.
82. Agostini I, Navarro JM, Rey F, et al. The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoterbound activator domains and binding to TFIIB. J Mol Biol 1996; 261: 599-606.
83. Iijima S, Nitahara-Kasahara Y, Kimata K, et al. Nuclear localization of Vpr is crucial for the efficient replication of HIV-1 in primary CD4 + T-cells. Virology 2004; 372: 249-61.
84. Kamata M, Nitahara-Kasahara Y, Miyamoto Y, Yoneda Y, Aida Y. Importin-alpha promotes passage through the nuclear pore complex of human immunodeficiency virus type 1 Vpr. J Virol 2005; 79: 3557-64.
85. Jacquot G, Le Rouzic E, David A, et al. Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. Retrovirology 2007; 4: 84.
86. Le Rouzic E, Mousnier A, Rustum C, et al. Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1. J Biol Chem 2002; 277: 45091-8.
87. Fouchier RA, Meyer BE, Simon JH, et al. Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol 1998; 72: 6004-13.
88. Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Weiner DB. Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol 1997; 71: 6339-47.
89. Votteler J, Studtrucker N, Sörgel S, et al. Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo. J Virol 2007; 81: 9572-6.
90. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol 1995; 69: 7909-16.
91. Mahalingam S, Khan SA, Jabbar MA, Monken CE, Collman RG, Srinivasan A. Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation. Virology 1995; 207: 297-302.
92. Mahalingam S, Collman RG, Patel M, Monken CE, Srinivasan A. Role of the conserved dipeptide Gly75 and Cys76 on HIV-1 Vpr function. Virology 1995; 210: 495-500.
93. Paxton W, Connor RI, Landau NR. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 1993, 67: 7229-37.
94. Singh SP, Tomkowicz B, Lai D, et al. Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr. J Virol 2000; 74:10650-7.
95. Zhao Y, Chen M, Wang B, et al. Functional conservation of HIV-1 Vpr and variability in a mother-child pair of long-term non-progressors. Virus Res 2002; 89: 103-21.
96. Hrecka K, Gierszewska M, Srivastava S, et al. Lentiviral Vpr usurps Cul4-DDB1VprBP E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci USA 2007; 104: 11778-83.
97. Nishizawa M, Myojin T, Nishino Y, Nakai Y, Kamata M, Aida Y. A carboxy-terminally truncated form of the Vpr protein of human immunodeficiency virus type 1 retards cell proliferation independently of G(2) arrest of the cell cycle. Virology 1999; 263: 313-22.
98. Bolton DL, Lenardo MJ. Vpr cytopathicity independent of G2/M cell cycle arrest in human immunodeficiency virus type 1-infected CD4 + T cells. J Virol 2007; 81: 8878-90.
99. Tan L, Ehrlich E, Yu XF. DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol 2007; 81: 10822-30.
100. Andersen JL, DeHart JL, Zimmerman ES, et al. HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog 2006; 2: e127.
101. Agostini I, Navarro JM, Bouhamdan M, et al. The HIV-1 Vpr co-activator induces a conformational change in TFIIB. FEBS Lett 1999; 450: 235-9.
102. Jian H, Zhao LJ. Pro-apoptotic activity of HIV-1 auxiliary regulatory protein Vpr is subtype-dependent and potently enhanced by nonconservative changes of the leucine residue at position 64. J Biol Chem 2003; 278: 44326-30.
103. Kamata M, Aida Y. Two putative alpha-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two mechanisms. J Virol 2000; 74: 7179-86.
104. Kitayama H, Miura Y, Ando Y, Hoshino S, Ishizaka Y, Koyanagi Y. Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. J Virol 2008; 82: 2528-42.
105. Sherman MP, de Noronha CM, Eckstein LA, et al. Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages. J Virol 2003; 77: 7582-9.